On March 20, 2026, Federal Trade Commission (“FTC”) Chairman Andrew Ferguson announced the formation of an internal Healthcare Task Force (the “Task Force”) and, in a memorandum issued the same day, directed the FTC’s Bureaus of Competition, Consumer Protection, and Economics, along with the Office of Policy Planning and the Office of Technology, to form the Task Force with the intention of coordinating the FTC’s existing health care enforcement and advocacy efforts across the agency.

What the Task Force Does—and Does Not—Do

The Task Force is designed primarily as a coordination and information‑sharing body across the FTC’s bureaus and related offices. Through this move, the FTC aims to leverage existing health care expertise to align enforcement priorities, share resources and identify advocacy opportunities.

The FTC has long maintained dedicated health care antitrust and consumer protection staff, including teams responsible for hospital and provider merger review. The Task Force does not replace those functions, nor does it create a new layer of substantive review.

Related HSR Developments

Earlier this week, we published an alert addressing the Fifth Circuit’s decision to stay implementation of the FTC’s updated Hart‑Scott‑Rodino (“HSR”) filing requirements, allowing parties to revert to the prior HSR form. Separately, on March 25, 2026, the FTC issued a notice requesting public comment on a potential new HSR rulemaking. While the public comment process is distinct from the pending litigation, it signals that even if the Fifth Circuit ultimately affirms the district court’s ruling on the merits, the FTC intends to pursue a revised HSR rule through a new rulemaking process, presumably informed by the courts’ guidance.

Practical Impact for Health Care Providers

While the announcement may sound significant, the practical impact is likely modest:

  • No material change to health care merger review. The FTC’s substantive standards, legal framework and review authority for hospital and provider transactions remain unchanged. Merger review will still be handled by the Bureau of Competition and existing health care merger teams, which will use the same analytical approaches applied prior to the Task Force’s creation.
  • Potential for greater internal coordination. The Task Force may facilitate closer coordination between merger review and non‑merger enforcement efforts, including scrutiny of related conduct such as contracting practices, data use or marketing claims. This coordination, however, reflects internal alignment rather than a new layer of regulatory review.
  • Reinforcement of FTC’s sustained focus on health care. The initiative underscores that health care remains a priority enforcement area for the FTC, consistent with recent antitrust activity.
  • No immediate effect on deal timelines or review mechanics. Parties should not expect changes to HSR filing requirements, review timelines or substantive standards as a result of the Task Force alone. Any effects are more likely to be incremental and case‑specific rather than structural or systemic.

If you have any questions or would like additional information about this topic, please contact one of the following members of Hall Render’s Antitrust Practice:

Hall Render blog posts and articles are intended for informational purposes only. For ethical reasons, Hall Render attorneys cannot give legal advice outside of an attorney-client relationship.

The post FTC Announces Formation of Healthcare Task Force appeared first on Law Firm | Health Care Law Firm in the USA | Hall Render.